PMID- 37234959
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230528
IS  - 1687-966X (Print)
IS  - 1687-9678 (Electronic)
VI  - 2023
DP  - 2023
TI  - Spermidine Retarded the Senescence of Multipotent Mesenchymal Stromal Cells In 
      Vitro and In Vivo through SIRT3-Mediated Antioxidation.
PG  - 9672658
LID - 10.1155/2023/9672658 [doi]
LID - 9672658
AB  - Multipotent mesenchymal stromal cells (MSCs) expand in vitro and undergo 
      replicative senescence, thereby restricting their clinical utilization. Thus, an 
      effective strategy is required to impede MSC senescence. Since spermidine (SPD) 
      supplementation can prolong the lifespan of yeast by inhibiting oxidative stress, 
      spermidine is a potential option for delaying MSC senescence. In this study, to 
      test our hypothesis, we first isolated primary human umbilical cord mesenchymal 
      stem cells (hUCMSCs). Subsequently, the appropriate SPD dose was administered 
      during continuous cell cultivation. Next, we evaluated the antisenescence effects 
      by SA-beta-gal staining, Ki67 expression, reactive oxygen species (ROS) levels, 
      adipogenic or osteogenic ability, senescence-associated markers, and DNA damage 
      markers. The results revealed that early SPD intervention significantly delays 
      the replicative senescence of hUCMSCs and constrains premature H(2)O(2)-induced 
      senescence. Additionally, by silencing SIRT3, the SPD-mediated antisenescence 
      effects disappear, further demonstrating that SIRT3 is necessary for SPD to exert 
      its antisenescence effects on hUCMSCs. Besides, the findings of this study also 
      suggest that SPD in vivo protects MSCs against oxidative stress and delays cell 
      senescence. Thus, MSCs maintain the ability to proliferate and differentiate 
      efficiently in vitro and in vivo, which reflects the potential clinical 
      utilization of MSCs in the future.
CI  - Copyright (c) 2023 Hua Huang et al.
FAU - Huang, Hua
AU  - Huang H
AUID- ORCID: 0000-0002-7042-1658
AD  - Department of Urology, The First Affiliated Hospital and College of Clinical 
      Medicine of Henan University of Science and Technology, Luoyang 471003, China.
AD  - The Center of Reproductive Medicine, The First Affiliated Hospital and College of 
      Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, 
      China.
FAU - Zhang, Wen
AU  - Zhang W
AD  - Department of General Medicine, The First Affiliated Hospital and College of 
      Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, 
      China.
FAU - Su, Junjie
AU  - Su J
AD  - Department of Urology, The First Affiliated Hospital and College of Clinical 
      Medicine of Henan University of Science and Technology, Luoyang 471003, China.
FAU - Zhou, Bisheng
AU  - Zhou B
AD  - Department of Urology, The First Affiliated Hospital and College of Clinical 
      Medicine of Henan University of Science and Technology, Luoyang 471003, China.
FAU - Han, Qingjiang
AU  - Han Q
AD  - Department of Urology, The First Affiliated Hospital and College of Clinical 
      Medicine of Henan University of Science and Technology, Luoyang 471003, China.
LA  - eng
PT  - Journal Article
DEP - 20230517
PL  - United States
TA  - Stem Cells Int
JT  - Stem cells international
JID - 101535822
PMC - PMC10208764
COIS- The authors declare that they have no competing interests.
EDAT- 2023/05/26 19:15
MHDA- 2023/05/26 19:16
PMCR- 2023/05/17
CRDT- 2023/05/26 12:20
PHST- 2022/10/05 00:00 [received]
PHST- 2023/04/18 00:00 [revised]
PHST- 2023/04/29 00:00 [accepted]
PHST- 2023/05/26 19:16 [medline]
PHST- 2023/05/26 19:15 [pubmed]
PHST- 2023/05/26 12:20 [entrez]
PHST- 2023/05/17 00:00 [pmc-release]
AID - 10.1155/2023/9672658 [doi]
PST - epublish
SO  - Stem Cells Int. 2023 May 17;2023:9672658. doi: 10.1155/2023/9672658. eCollection 
      2023.